Back to top
more

Liquidia Technologies (LQDA)

(Delayed Data from NSDQ)

$12.06 USD

12.06
637,053

-0.42 (-3.37%)

Updated May 10, 2024 04:00 PM ET

After-Market: $12.06 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

ANI Pharmaceuticals (ANIP) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

ANI (ANIP) delivered earnings and revenue surprises of 11.76% and 8.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Cytokinetics (CYTK) delivered earnings and revenue surprises of -18.85% and 73.77%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Allogene Therapeutics (ALLO) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 7.04% and 6%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Vericel Corporation (VCEL) Q4 Earnings Surpass Estimates

by Zacks Equity Research

Vericel Corporation (VCEL) delivered earnings and revenue surprises of 500% and 0.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Liquidia Technologies, Inc. (LQDA): Can Its 9.7% Jump Turn into More Strength?

by Zacks Equity Research

Liquidia Technologies, Inc. (LQDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Are Medical Stocks Lagging Assertio (ASRT) This Year?

by Zacks Equity Research

Here is how Assertio (ASRT) and Liquidia Technologies, Inc. (LQDA) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Assertio (ASRT) This Year?

by Zacks Equity Research

Here is how Assertio (ASRT) and Liquidia Technologies, Inc. (LQDA) have performed compared to their sector so far this year.

Wall Street Analysts Think Liquidia Technologies, Inc. (LQDA) Could Surge 153%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 153.2% in Liquidia Technologies, Inc. (LQDA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Is Liquidia Technologies (LQDA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Liquidia Technologies, Inc. (LQDA) and Assertio (ASRT) have performed compared to their sector so far this year.

Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 22.22% and 9.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Are Medical Stocks Lagging Acadia Healthcare (ACHC) This Year?

by Zacks Equity Research

Here is how Acadia Healthcare (ACHC) and Liquidia Technologies, Inc. (LQDA) have performed compared to their sector so far this year.

Wall Street Analysts Believe Liquidia Technologies, Inc. (LQDA) Could Rally 136%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Liquidia Technologies, Inc. (LQDA) points to a 136.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Is Liquidia Technologies (LQDA) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Liquidia Technologies, Inc. (LQDA) and PolyPid Ltd. (PYPD) have performed compared to their sector so far this year.

Benjamin Rains headshot

Find Highly-Ranked Cheap Stocks Under $10 to Buy with this Screen

by Benjamin Rains

We used one of our Zacks screens to help show investors how to find strong, highly-ranked stocks that are trading for under $10 per share to consider buying as we start to close out August.

Here's Why Liquidia Technologies, Inc. (LQDA) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Liquidia Technologies, Inc. (LQDA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Wall Street Analysts Believe Liquidia Technologies, Inc. (LQDA) Could Rally 74%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 74.1% in Liquidia Technologies, Inc. (LQDA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 37.50% and 11.66%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cara (CARA) delivered earnings and revenue surprises of 71.43% and 8.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 32.56% and 2.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Is IQ Chaikin U.S. Small Cap ETF (CSML) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for CSML

Should IQ Chaikin U.S. Small Cap ETF (CSML) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for CSML

United Therapeutics (UTHR) Gains on Tyvaso DPI Approval

by Zacks Equity Research

The FDA approves United Therapeutics' (UTHR) drug-device combination therapy, Tyvaso DPI, for PAH patients. It is a dry-powder inhalation formulation of Treprostinil. Stock gains 8.8%.

Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -50% and 7.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Aveanna Healthcare (AVAH) Q1 Earnings Lag Estimates

by Zacks Equity Research

Aveanna (AVAH) delivered earnings and revenue surprises of -33.33% and 4.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Epizyme (EPZM) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Epizyme (EPZM) delivered earnings and revenue surprises of -11.43% and 19.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?